MUNICH, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today favorable results from its ...
In this study, an individualized dosing regimen of GH001, a synthetic inhaled formulation of mebufotenin, resulted in significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results